US Stock Insider Trading | Alphatech Holdings Disclosed Three Insider Transactions on March 9

robot
Abstract generation in progress

On March 9, 2026, Alphatec Holdings (ATEC) disclosed three insider transactions. Director Miles Patrick sold 219,700 shares on March 5, 2026.

【Recent Insider Transactions】

Disclosure Date Position Name Transaction Date Buy/Sell Quantity Price per Share/USD Total Amount/USD
March 9, 2026 Executive Marshall Tyson Eliot March 5, 2026 Sell 88,800 12.49 1,109,500
March 9, 2026 Director Miles Patrick March 5, 2026 Sell 219,700 12.57 2,762,200
March 9, 2026 Executive Koning John Todd March 5, 2026 Sell 68,900 12.57 866,200
February 17, 2026 Executive Hunsaker Craig E February 12, 2026 Buy 120,200 1.68 202,000
February 17, 2026 Executive Hunsaker Craig E February 12, 2026 Sell 41,100 13.10 538,500
February 17, 2026 Executive Hunsaker Craig E February 12, 2026 Buy 21,000 3.09 64,800
February 17, 2026 Executive Hunsaker Craig E February 12, 2026 Buy 78,200 2.69 210,500
February 17, 2026 Executive Hunsaker Craig E February 12, 2026 Buy 31,700 1.93 61,200
February 6, 2026 Executive Sponsel David February 5, 2026 Sell 60,400 13.79 833,300
February 4, 2026 Executive Hunsaker Craig E February 3, 2026 Sell 37,400 14.71 549,500

【Company Profile】

Alphatec Holdings, Inc. was incorporated in Delaware in March 2005. The company is a medical technology firm dedicated to designing, developing, manufacturing, and selling surgical products for spinal disease treatment, focusing on factors affecting spinal aging. The company offers a comprehensive product portfolio and pipeline addressing cervical and thoracic intervertebral regions, covering various spinal conditions. Its main products target the global orthopedic spinal disease market. The company emphasizes collaboration with spine surgeons to design and co-develop a range of products. It has advanced manufacturing equipment, providing a unique competitive advantage and enabling rapid delivery of solutions to meet urgent needs of doctors and patients. Its products and systems, with enhanced functionality, attract surgeons, offering a complete suite of solutions for safe and successful spinal surgeries. All implants sold in the U.S. are approved by the Food and Drug Administration. The company’s strategic goal is to become a leading independent global spine company focused on solutions for spinal aging. Spinal aging has unique characteristics, and its solutions target patients with osteoporosis, vertebral compression fractures, scoliosis, disc degeneration, or spinal stenosis. To further differentiate its offerings, the company has integrated minimally invasive techniques and biologics into its product portfolio to improve patient outcomes.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin